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Ljungan virus (LV) has not confirmed to associate with any human disease, but a possible 
connection with type 1 diabetes (T1D) has been suggested. Ljungan virus (LV) is a rodent-borne 
picornavirus that induces a diabetes-like condition in rodents. Approximately 30% of adults and 
60% of children are seropositive in Finland. The Finnish Type 1 Diabetes Prediction and 
Prevention (DIPP) study enabled the use of very well characterized sample panels from children 
seroconverted to positivity for multiple islet autoantibodies during their prospective observation 
from birth, in addition samples from age, sex, HLA and residence area matched control children.  
Methods 
We analyzed LV IgG seroprevalence in 102 case children (65 had also developed T1D), in 
addition to non-diabetic control children. LV and human parechovirus (HPeV) 
immunofluorescence assays were used to analyze LV and HPeV specific IgG from 102 plasma 
samples taken at the time of islet autoantibody appearance, and from 204 samples from the 
matched control children.  
Results 
Altogether 46.1% of the case and 50.7% of the control children were positive for LV IgG (odds 
ratio 0.8, 95% CI 0.47-1.36, p=0.416), and 67.6% vs. 79.8% were positive for HPeV IgG, 
respectively (odds ratio 0.49, 0.27-0.9, p=0.023).  
Conclusions: 
Thus, no risk associations between LV or HPeV -specific IgG, and islet autoimmunity were 
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children (p=0.023) suggests a possible protective association of this virus with islet 
autoimmunity. 











Parechoviruses (Picornaviridae: Picornavirus) are small non-enveloped single-stranded RNA 
viruses. The genus Parechovirus comprises four species, and species of Parechovirus A 
[formerly Human parechovirus (HPeV)] and Parechovirus B [formerly Ljungan virus (LV)] 
consist of 16 HPeV and 4 LV types, (www.picornaviridae.com website, November 2017). LV is 
a rodent-borne virus (1) while HPeVs infect humans with symptoms including mild 
gastrointestinal and respiratory infections in children, and neonatal sepsis-like disease and 
encephalitis in infants (2).   
The external triggers of human type 1 diabetes (T1D) have been the subject of extensive 
research, and certain virus infections, particularly enteroviruses have been implicated as the main 
candidates (3). Possible association of LV and diabetes has been studied using both nucleic acid 
detection methods and serological methods. In a MIDIA cohort study (4), LV RNA was not 
detected in stool samples collected from children in Norway. In Sweden, LV IgG antibodies 
were found to be associated with both positivity for HLA-DQB1*0302 (DQ8) allele and T1D-
associated islet autoantibodies (5, 6). In addition to LV IgG, the prevalence of HPeV IgG was 
also increased in T1D patients with insulin autoantibodies and HLA-DQ8 when analyzed using 
multiplex immunoassay. However, the authors stated that cross-reactions could not be ruled out 
with this assay (6).  
Our aim was to screen both LV- and HPeV-specific IgG antibodies from children who have 
seroconverted for multiple T1D-associated autoantibodies as a marker of an ongoing beta-cell 
damaging process and from their matched healthy control children in the DIPP study. This study 
design enabled the identification of infections which preceded the initiation of the beta-cell 










All study subjects were participants in the DIPP study. The present study cohort included 
children recruited at the University Hospital in Tampere. Blood samples were drawn at the ages 
of 3, 6, 12, 18, and 24 months and once a year thereafter, and all follow-up sera were screened 
for T1D-associated autoantibodies [islet cell autoantibodies (ICA) as well as autoantibodies to 
insulin (IAA), glutamic acid decarboxylase 65 (GADA) and the protein tyrosine phosphatase-
related IA-2 antigen (IA-2A)]. The DIPP study has been approved by the ethical committees of 
the participating university hospitals. A written informed consent was obtained from all 
participating families.   
The following criteria were used to select children for the nested case-control study:  The case 
children (N=102, 64% males) had turned positive for two or more of the T1D-associated 
autoantibodies mentioned above and remained autoantibody positive in all later follow-up 
samples. Of these, 65 have also progressed to clinical T1D. Two autoantibody negative and non-
diabetic control subjects (N=203, only one control child was available for one of the case 
children) were selected for each case child and matched for time of birth (± 2 months), age at 
sample collection (± 3 months), sex and T1D-associated HLA-DQ alleles. The first autoantibody 
positive sample of the case children and the corresponding sample from their matched control 
children were selected for virus antibody analyses (median age was 48 months and range 17-133 
months at sample collection). The children were born in 1995-2009. 
Diabetes-Associated Autoantibodies and HLA Genotyping 
ICA was analyzed using indirect immunofluorescence assay (IFA) and IAA, GADA and IA-2A 
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against, type 1 diabetes were identified by analyzing HLA-DQB1 alleles (DQB1*02, *03:01, 
*03:02, and *06:02/3) from cord blood of the children. The genotyping was based on lanthanide 
labeled oligonucleotide probe hybridization and time-resolved fluorometric detection (8). 
Children carrying the high-risk HLA-DQB1*02/DQB1*0302 genotype or the moderate-risk 
DQB1*0302/x genotype (x ≠ DQB1*03:02, *06:02, or *06:03) were invited for follow-up. The 
diagnosis of type 1 diabetes was based on the World Health Organization criteria. 
Virus antibodies 
LV- and HPeV-specific IgG was detected using LV (LV strain 145SLG; described in 
Jääskeläinen et al. 2013) and HPeV IFAs. The HPeV IFA was set up using HPeV1 strain Harris 
and the method described in Jääskeläinen et al. (9), and was further evaluated by comparing the 
results with those obtained from 9 LV-antibody negative plasma samples using a HPeV 
microneutralization assay (MNT; 10). Two commercial hyperimmune antisera against HPeV1 
and HPeV2 [VR-1063AS/HO™, VR-1064AS/HO™; produced in horse, LGC Standards 
(ATCC), Teddington, United Kingdom] were used as controls.  
Statistical Analyses 
The prevalence of virus antibodies in both case and control groups was analyzed using 
conditional logistic regression and STATA 12.1 statistical software (StataCorp, College Station, 
TX, USA). A p value of less than 0.05 was set as indicator of statistical significance. 
Results 
In the comparison of HPeV IFA test with microneutralization assay, concordant results were 
obtained and HPeV IFA detected all HPeV1-6 types (8 positive samples). The titers for HPeV1-6 
varied from 64 until 16384, and LV IFA was negative in all cases. One MNT negative sample 
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seropositive for LV IgG and 76% (231/305) HPeV IgG in IFA. Only one child was HPeV 
negative but LV positive. However, 84 children (27.5%; 84/505) were HPeV positive but LV 
negative (Table 1). The prevalence of LV antibodies did not differ between the case and control 
children (Table 1). This was also true when only those case children who progressed to clinical 
T1D and their controls were included. However, case children tended to be less frequently 
positive for HPeV antibodies than control children (Table 1). This trend was observed in both 
younger and older children and it was particularly clear among boys and in the subgroup of cases 
that had progressed to clinical T1D. Similar trend was further seen in children who developed 
IAA as the first appearing autoantibody and in those who seroconverted first to positivity for 
GADA (data not shown). The parallel presence of antibodies against LV and HPeV showed a 
significant correlation (χ2 = 69.04, df = 1, p < 0.00001) in whole study cohort.  
Discussion 
LV infections have been linked to human T1D in some studies (16, 17) but prospective studies 
are lacking. In this study, both LV (49%) and HPeV (76%) antibodies were frequently detected. 
LV IFA was previously evaluated and no cross-reactivity was detected for HPeV1-2 and 4-6 (9). 
In the present study we tested the HPeV IFA using plasma samples positive for neutralizing 
antibodies (MNT) against HPeV1-6. All MNT positive samples were positive by HPeV IFA but 
negative by LV IFA.  
LV seropositivity was not associated with the beta-cell damaging process as 46% of the case 
children, compared to 51% of their age, sex and HLA matched control children, were positive for 
LV antibodies (p=0.416). This was also the case for HPeV IFA where 68% vs. 80% of the 
children analyzed were positive (p=0.023), respectively. Thus, the prevalence of HPeV 
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difference is not known. Overall, the control children were more HPeV seropositive than cases 
(p=0.023), especially when the group of clinical TD1, boys and children over three years were 
examined (p=0.007, 0.009, 0.029, respectively; Table 2). The case children had no diabetes-
associated metabolic changes, since the virus antibodies were analyzed in the early prediabetic 
phase when the children were still normoglycaemic. However, we cannot exclude the possibility 
that the function of the immune system is affected by the autoimmune process, leading to lower 
levels in HPeV antibodies. Alternatively, it is possible that HPeV infections could somehow 
protect against islet autoimmunity, possibly by stimulating the protective elements of the gut 
immune system. Accordingly, for enteroviruses, a link between infections with low-virulence 
virus strains and protection against T1D has been suggested (11). It should also be noted that 
maternal virus antibodies could not have biased these findings since all children were older than 
one year and maternal antibodies should have disappeared by that age. 
In Sweden, HLA-DQB*0302 and islet autoantibodies, particularly insulin autoantibodies, were 
suggested to be associated with LV and HPeV IgG antibodies (5, 6). In Norway and Finland, the 
children participating in the MIDIA and DIPP studies, respectively, were studied for 
parechovirus nucleic acids and/or antibodies by Tapia et al. (4), and Zhao et al. (12). No LV 
RNA positive feces in the MIDIA cohort (4) nor DIPP cohort (12). All children in the analyzed 
DIPP cohort samples have been DQB1*0302 positive based on earlier eligibility criteria and it 
has thus not been possible to explore the HLA association here.  
This is a prospective study covering the time before the initiation of islet autoimmunity. This is 
the strength of this study, as well as, that the control children were carefully matched with to 
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However, this study was carried out only in Finland, and this can be considered as a limitation to 
make any final conclusions.     
The data also indicated that control children were statistically more positive for HPeV than case 
group, even when clinically T1D cases were analyzed. This is interesting finding, and raised the 
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Table 1. Prevalence of LV and HPeV antibodies in children with β-cell autoimmunity (case 
children) and autoantibody-negative control children. 
Group (N= in total) Seroprevalence of 









N (%)   
OR 95% CI p-
value
3 
Summary of all   
(Cases N=102, Controls N=203;  
All N=305) 
LV  47 (46.1) 103 (50.7) 0.80  0.47, 1.36 0.416 
HPeV 69 (67.6) 162 (79.8) 0.49 0.27, 0.90 0.023 
LV and HPeV  45 (44.1) 102 (50.2) 0.77 0.45, 1.33 0.354 
LV pos, HPeV neg    0 (0) 1 (0.5) NA NA NA 
HpeV pos,  LV neg 24 (23.5) 60 (30.5) 0.67 0.36-1.23 0.196 
Divided by sex  
(Cases N=102, 




LV  27 (42.2) 68 (53.1) 0.56 0.28, 1.12 0.102 
HPeV 41 (65.1) 104 (81.2) 0.35 0.16, 0.77 0.009 
Girls (N=113) LV  20 (52.6) 35 (46.7) 1.35 0.59, 3.12 0.481 
HPeV 29 (78.4) 59 (79.7) 0.91 0.31, 2.62 0.855 
Divided by age 
of 3 years 
(Cases N=102, 
Controls N=203;  
All N=305) 
Age ≤3 years  LV  16 (47.1) 31 (45.6) 1.09 0.41, 2.89 0.868 
HPeV 22 (64.7) 49 (73.1) 0.63 0.22, 1.77 0.380 
Age >3 years  LV  31 (45.6) 72 (53.3) 0.71 0.38, 1.33 0.283 
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**Cases progressed to T1D  
(N=65 cases, their child 
matched controls N = 129) 
LV  33 (50.8) 66 (51.2) 1.00 0.51, 1.95 1.000 
HPeV 43 (66.2) 107 (82.9) 0.35 0.17, 0.75 0.007 
LV, Ljungan virus; HPeV, human parechovirus; T1D, type 1 diabetes; NA, not applicable;.  
1
 in total 102 children, gender: 64 males/38 females
 
2
 in total 203 children, gender: 128 males/75 females 
3
 p-value <0.05 considered significant 
** In total, 65 individual cases progressed to clinical T1D. None of the matched control children 
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